Stocks Health care CPIX
NASDAQ · Health careCumberland Pharmaceuticals Inc (CPIX)
Cumberland Pharmaceuticals Inc brought in $39.9M of revenue over the twelve months to June 30, 2026, down 5.2% from a year earlier. It posted a net loss of $10.9M. Operating cash flow minus capital spending left $4.8M of free cash flow in fiscal 2025. At June 30, 2026 it held $3.9M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 7, 2026.
Key facts about Cumberland Pharmaceuticals Inc
- Net worth
- Cumberland Pharmaceuticals Inc has a market value (market cap) of $80.5M at the latest share price, and shareholders' equity of $17.4M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $44.5M (+17.6% year on year), with a net loss of $2.8M. Over the 12 months to June 30, 2026: revenue $39.9M, net loss $10.9M.
- Cash flow
- In fiscal 2025 operations brought in $4.9M of cash; after $97.9K of capital spending, free cash flow was $4.8M.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 7, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Cumberland Pharmaceuticals Inc's next report was expected around November 3, 2026 and is not on file with the SEC yet.
What Cumberland Pharmaceuticals Inc does
Cumberland Pharmaceuticals Inc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker CPIX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $44.5M | -$2.8M | -$0.19 | $4.8M |
| 2024 | $37.9M | -$6.5M | -$0.46 | -$678.6K |
| 2023 | $39.6M | -$6.3M | -$0.44 | $5.8M |
| 2022 | $42M | -$5.6M | -$0.38 | $8.4M |
| 2021 | $36M | -$3.5M | -$0.24 | $6.2M |
| 2020 | $37.4M | -$3.3M | -$0.22 | $5.3M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where CPIX ranks in Health care
Latest SEC filings
What Cumberland Pharmaceuticals Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 26, 2026
- October 23, 2026Other event 8-K
- September 11, 2026Shareholder vote results 8-K/A
- August 28, 2026
- August 7, 2026Quarterly report 10-Q · period to June 30, 2026Revenue fell 19% to $8.8M versus the same quarter last year; diluted EPS -$0.29 versus -$0.05.
- August 4, 2026
- July 13, 2026Other event 8-K
- July 1, 2026
- June 25, 2026
- May 26, 2026Merger proxy statement DEFM14A
What is CPIX worth? A DCF from its reported cash flow
Insider trades
What the people running Cumberland Pharmaceuticals Inc did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| March 18, 2026 | Young CarolineDirector | Received as pay | 1,800 | $5K |
| March 18, 2026 | Krogulski KennethDirector | Received as pay | 1,800 | $5K |
| March 18, 2026 | Krogulski KennethDirector | Received as pay | 4,000 | $11.2K |
| March 18, 2026 | Jones JamesDirector | Received as pay | 1,800 | $5K |
| March 18, 2026 | Brown Martin S JRDirector | Received as pay | 1,800 | $5K |
| March 18, 2026 | Galante Joseph CDirector | Received as pay | 1,800 | $5K |
| March 16, 2026 | Kazimi A JChairman and CEO, Director, 10% owner | Shares withheld for tax | 5,845 | $17.9K |
| December 31, 2025 | Krogulski KennethDirector | Other change | 62 | $242.4 |
Who owns CPIX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| A.J. Kazimi13G, passive | 38.4% | February 9, 2026 |
Largest institutional holders
Insiders
6 insiders reported holding 6,153,576 shares in total, about $33M at the last price.
| Holder | Shares |
|---|---|
| Kazimi A JChairman and CEO, Director, 10% owner | 5,695,310 |
| Krogulski KennethDirector | 302,338 |
| Galante Joseph CDirector | 63,656 |
| Jones JamesDirector | 46,863 |
| Young CarolineDirector | 35,109 |
| Brown Martin S JRDirector | 10,300 |
Questions about CPIX
What does Cumberland Pharmaceuticals Inc do?
Cumberland Pharmaceuticals Inc is a company in the Health care sector, listed on NASDAQ as CPIX. Its shares trade on NASDAQ under the ticker CPIX.
What is Cumberland Pharmaceuticals Inc's net worth?
Cumberland Pharmaceuticals Inc has a market value (market cap) of $80.5M at the latest share price, and shareholders' equity of $17.4M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Cumberland Pharmaceuticals Inc profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $10.9M on revenue of $39.9M.
How much revenue does Cumberland Pharmaceuticals Inc make?
Over the twelve months to June 30, 2026 Cumberland Pharmaceuticals Inc reported revenue of $39.9M. That is 5.2% less than a year earlier.
When did Cumberland Pharmaceuticals Inc last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 7, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the investor disclosure from October 26, 2026.
When is Cumberland Pharmaceuticals Inc's next earnings report?
Cumberland Pharmaceuticals Inc's next report was expected around November 3, 2026 and is not on file with the SEC yet.
Similar companies
Compare CPIX with
Follow CPIX
Get an email when Cumberland Pharmaceuticals Inc files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Cumberland Pharmaceuticals Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.